| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 12/13/2001 | WO2001094620A1 Screening-method for modulators of methyltransferase-dependent chromosome stability |
| 12/13/2001 | WO2001094612A2 Method for identifying medically valuable active substances |
| 12/13/2001 | WO2001094587A2 Extracellular messengers |
| 12/13/2001 | WO2001094582A1 Novel g protein-coupled receptor protein and dna thereof |
| 12/13/2001 | WO2001094581A1 Tumour suppressor and uses thereof |
| 12/13/2001 | WO2001094568A1 A NEW POLYPEPTIDE- HUMAN II CLASS AMINOACYL-tRNA SYNTHETASE 10 AND THE POLYNUCLEOTIDE ENCODING IT |
| 12/13/2001 | WO2001094567A1 A new polypeptide- human sailor transposase 11 and the polynucleotide encoding it |
| 12/13/2001 | WO2001094553A1 Method of amplifying natural killer t cells |
| 12/13/2001 | WO2001094529A2 A novel polypeptide, a human atp dependant serine proteinase 21 and the polynucleotide encoding the polypeptide |
| 12/13/2001 | WO2001094420A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | WO2001094415A2 Nuclear hormone receptor |
| 12/13/2001 | WO2001094413A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | WO2001094405A1 A new polypeptide- nerve synapse ion channel-associated chapsyn-110 and the polynucleotide encoding it |
| 12/13/2001 | WO2001094404A1 A new polypeptide- human l1 retroposon 22 and the polynucleotide encoding it |
| 12/13/2001 | WO2001094403A1 A new polypeptide- human transcriptional activation subunit 14 and the polynucleotide encoding it |
| 12/13/2001 | WO2001094402A1 A new polypeptide---human npat protein 12 and the polynucleotide encoding it |
| 12/13/2001 | WO2001094401A1 A new polypeptide-human npat protein 15 and the polynucleotide encoding it |
| 12/13/2001 | WO2001094397A1 A novel polypeptide-zinc finger protein 79.46 and the polynucleotide encoding said polypeptide |
| 12/13/2001 | WO2001094391A2 Intracellular signaling proteins |
| 12/13/2001 | WO2001094357A1 Antitumoral compounds |
| 12/13/2001 | WO2001094353A1 Thiophene derivatives useful as anticancer agents |
| 12/13/2001 | WO2001094351A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | WO2001094347A1 Tetracyclic diketopiperazine compounds as pdev inhibitors |
| 12/13/2001 | WO2001094341A1 Quinazoline derivatives for the treatment of tumours |
| 12/13/2001 | WO2001094340A1 Heterocyclic hydrazones for use as anti-cancer agents |
| 12/13/2001 | WO2001094325A1 2-aminothiazoline derivatives and their use as no-synthase inhibitors |
| 12/13/2001 | WO2001094312A2 Indolinone derivatives as protein kinase/phosphatase inhibitors |
| 12/13/2001 | WO2001094293A2 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | WO2001094279A2 Purification of xanthophylls from marigold extracts that contain high levels of chlorophylls |
| 12/13/2001 | WO2001093983A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 12/13/2001 | WO2001093913A2 T cell receptor fusions and conjugates and methods of use thereof |
| 12/13/2001 | WO2001093909A2 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
| 12/13/2001 | WO2001093901A1 Combined preparation for the treatment of neoplasic diseases |
| 12/13/2001 | WO2001093900A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 12/13/2001 | WO2001093897A2 Angiostatin and endostatin binding proteins and methods of use |
| 12/13/2001 | WO2001093885A1 Therapeutic agents - ii |
| 12/13/2001 | WO2001093884A1 Therapeutic agents - i |
| 12/13/2001 | WO2001093883A1 Therapeutic agents - iii |
| 12/13/2001 | WO2001093882A1 Purified material having size and growth inhibitory effects on cells and tissues |
| 12/13/2001 | WO2001093881A1 Immunological substance containing enteroabsorbable anti-inflammatory factor and application thereof |
| 12/13/2001 | WO2001093879A1 Biologically active agents and drugs |
| 12/13/2001 | WO2001093877A2 Epithelial cell cancer drug |
| 12/13/2001 | WO2001093867A1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors |
| 12/13/2001 | WO2001093851A2 Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3 |
| 12/13/2001 | WO2001093846A2 Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
| 12/13/2001 | WO2001093841A2 Barbituric acid analogs as therapeutic agents |
| 12/13/2001 | WO2001093836A2 Encapsulation of polynucleotides and drugs into targeted liposomes |
| 12/13/2001 | WO2001093828A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | WO2001093805A2 FUSION OF jAZF1 AND jjAZ1 GENES IN ENDOMETIRIAL STROMAL TUMORS |
| 12/13/2001 | WO2001068147A3 Synthetic oligonucleotides as inducers of erythroid differentiation |
| 12/13/2001 | WO2001044445A3 Human lyases and associated proteins |
| 12/13/2001 | WO2001043694A3 Compositions and methods for caspase-induced apoptosis |
| 12/13/2001 | WO2001037820A3 Ionizable indolinone derivatives and their use as ptk ligands |
| 12/13/2001 | WO2001035899A3 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 12/13/2001 | WO2001032139A3 Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
| 12/13/2001 | WO2001030987A3 Tankyrase h, compositions involved in the cell cycle and methods of use |
| 12/13/2001 | WO2001028577A3 Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain |
| 12/13/2001 | WO2001027245A3 Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells |
| 12/13/2001 | WO2001026682A3 Modified plant viruses and methods of use thereof |
| 12/13/2001 | WO2001020026A3 POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |
| 12/13/2001 | WO2001019399A3 Method of potentiating chemotherapy and treating solid tumors |
| 12/13/2001 | WO2001015722A3 Methods useful in affecting apoptosis |
| 12/13/2001 | WO2001011038A3 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| 12/13/2001 | WO2000069390A3 Compositions for improving bioavailability of orally administered drugs |
| 12/13/2001 | WO2000044888A3 Dimethylarginine dimethylaminohydrolases |
| 12/13/2001 | WO2000033857A9 Cancer treatment composition and method using natural plant essential oils |
| 12/13/2001 | WO2000029501A9 Radioactive coating solutions, methods, and substrates |
| 12/13/2001 | US20010051760 Use of photofrin as a radiosensitizer |
| 12/13/2001 | US20010051640 C7 carbamoyloxy substituted taxanes |
| 12/13/2001 | US20010051626 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 12/13/2001 | US20010051623 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic |
| 12/13/2001 | US20010051609 Administering Dna |
| 12/13/2001 | US20010051604 Mixture containing stabilizers, sodium chloride, buffer and surfactants |
| 12/13/2001 | US20010051595 Injection into blood |
| 12/13/2001 | DE10101324C1 New 1-(dimercaptoalkyl)-quinazoline-2,4(1H,3H)-diones, are stable matrix metalloproteinase inhibitors useful e.g. for treating rheumatism, tumor metastasis or sunburn |
| 12/13/2001 | DE10026833A1 Verfahren zur Identifizierung von Verbindungen zur Modulierung der Aktivität eines Tumorsuppressorgens A method for identifying compounds for modulating the activity of a tumor suppressor |
| 12/13/2001 | CA2810249A1 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2412436A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2412377A1 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | CA2411730A1 Tumour suppressor and uses thereof |
| 12/13/2001 | CA2411596A1 Therapeutic agents - ii |
| 12/13/2001 | CA2411542A1 Encapsulation of polynucleotides and drugs into targeted liposomes |
| 12/13/2001 | CA2411536A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | CA2411470A1 T cell receptor fusions and conjugates and methods of use thereof |
| 12/13/2001 | CA2411285A1 Combined preparation for the treatment of neoplasic diseases |
| 12/13/2001 | CA2411084A1 Thiophene derivatives useful as anticancer agents |
| 12/13/2001 | CA2411062A1 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | CA2411010A1 Tetracyclic diketopiperazine compounds as pdev inhibitors |
| 12/13/2001 | CA2410577A1 Method for treating respiratory disorders associated with pulmonary elastic fiber injury |
| 12/13/2001 | CA2410509A1 Indolinone derivatives as protein kinase/phosphatase inhibitors |
| 12/13/2001 | CA2410409A1 Antitumoral compounds |
| 12/13/2001 | CA2409392A1 Intracellular signaling proteins |
| 12/13/2001 | CA2409342A1 Extracellular messengers |
| 12/13/2001 | CA2409197A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 12/13/2001 | CA2409015A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | CA2408748A1 Nuclear hormone receptor |
| 12/12/2001 | EP1162273A1 Recombinant DNA vectors for gene therapy |
| 12/12/2001 | EP1162272A2 Generation of immune responses to prostate-specific antigen (SPA) |
| 12/12/2001 | EP1162201A2 Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
| 12/12/2001 | EP1161943A2 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds |